Patents by Inventor Xiaofang Wang

Xiaofang Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11899175
    Abstract: The present disclosure discloses an optical imaging lens assembly, sequentially from an object side to an image side along an optical axis, including: a first lens having refractive power, an object-side surface thereof is concave, and an image-side surface thereof is convex; a second lens having refractive power; a third lens having refractive power; a fourth lens having refractive power; a fifth lens having negative refractive power, and an object-side surface thereof is concave; a sixth lens having positive refractive power; and a seventh lens having refractive power. A total effective focal length f of the optical imaging lens assembly and an effective focal length f3 of the third lens may satisfy f3/f>1.49.
    Type: Grant
    Filed: November 2, 2020
    Date of Patent: February 13, 2024
    Inventors: Wuchao Xu, Kaiyuan Zhang, Xiaofang Wang, Ying Zhou, Fujian Dai, Liefeng Zhao
  • Patent number: 11867880
    Abstract: The present disclosure discloses an optical imaging system, sequentially from an object side to an image side of the optical imaging system along an optical axis, including: a first lens having refractive power; a second lens having negative refractive power; a third lens having refractive power; a fourth lens having positive refractive power; a fifth lens having refractive power; a sixth lens having refractive power; and a seventh lens having refractive power, a concave object-side surface, and a concave image-side surface. Half of a diagonal length ImgH of an effective pixel area on an imaging plane of the optical imaging system may satisfy ImgH>6.0 mm. A total effective focal length f of the optical imaging system and an entrance pupil diameter EPD of the optical imaging system may satisfy f/EPD<1.9.
    Type: Grant
    Filed: September 30, 2020
    Date of Patent: January 9, 2024
    Assignee: Zhejiang Sunny Optical Co., Ltd
    Inventors: Xiaofang Wang, Biao Xu, Kaiyuan Zhang, Fujian Dai, Liefeng Zhao
  • Patent number: 11768353
    Abstract: An optical imaging system includes an optical lens group including, sequentially along an optical axis from an object side to an image side, a first lens, a second lens, a third lens, and a fourth lens; a lens barrel, the optical lens group is accommodated in the lens barrel; and a plurality of spacers including at least two spacers disposed between the third lens and the fourth lens; the diameter D of the lens barrel at an end towards the object side and a maximum effective radius DT11 of an object-side surface of the first lens satisfy 2×DT11/D?0.5.
    Type: Grant
    Filed: September 21, 2020
    Date of Patent: September 26, 2023
    Assignee: ZHEJIANG SUNNY OPTICAL CO., LTD
    Inventors: Xiaofang Wang, Guijie Zhu, Biao Xu, Qi Chen, Kaiyuan Zhang, Fujian Dai, Liefeng Zhao
  • Publication number: 20230251203
    Abstract: A method for evaluating adverse reaction of sesquiterpenoids in zedoary turmeric oil is performed successively according to the following steps: (1) preparing a hemoglobin (Hb) solution and a to-be-determined solution; (2) taking Hb solutions with a same volume and respectively adding the same volume of the to-be-determined solution or normal saline thereto, mixing well and standing; (3) determining absorbance with a microplate reader, and comparing the absorbance of a to-be-determined solution group with the absorbance of a normal saline group to obtain a value r; wherein if r>1.5, then the result indicates that the concentration of the to-be-determined solution has a risk of causing dyspnea; wherein, r = OD OD Hb ; in the formula, OD is an absorbance at 280 nm wavelength of the to-be-determined solution after interacting with Hb; ODHb, is an absorbance at 280 nm wavelength of a blank control of normal saline after interacting with Hb.
    Type: Application
    Filed: April 26, 2021
    Publication date: August 10, 2023
    Applicant: BEIJING FRIENDSHIP HOSPITAL, CAPITAL MEDICAL UNIVERSITY
    Inventors: Dan YAN, Yan YAN, Xiaofang WANG, Zhenzhen WANG
  • Publication number: 20230104993
    Abstract: A technology of 3D printing integration of hard materials and cells, a preparation of bone-repair functional module with osteogenic microenvironment, bone organoid method and the application of quick repair of bone defects are provided. A preparation method of biological microenvironmental factors as independent osteogenic factors is further provided. The present integrated 3D printing technology realizes 3D printing of cells and hard materials synchronously by adjusting the temperature, so as to build a real sense of biomimetic bone tissue, which can be customized according to the specific defects and clinical needs of patients.
    Type: Application
    Filed: September 30, 2022
    Publication date: April 6, 2023
    Applicant: CHONGQING MEDICAL UNIVERSITY
    Inventors: Xiaolin TU, Yufei MA, Jun LI, Xian LI, Zhurong TANG, Zhengsong XIE, Jie CHEN, Xiaofang WANG, Guangliang LIU, Pengtao WANG, Bo WANG, Yisheng LUO, Yangxi LIU, Weimin GONG, Molin LI
  • Publication number: 20230089073
    Abstract: Provided herein are GLP-1 receptor modulator compounds, pharmaceutical compositions, methods of their preparation, and methods of their use in treatment, and/or diagnosis.
    Type: Application
    Filed: January 27, 2022
    Publication date: March 23, 2023
    Inventors: Xiaohui DU, Ray Fucini, Xu Ran, Chien-Hung Yeh, Xiang Zhou, Rui Gao, Joon Won Jeong, Li Liu, Subas Man Sakya, Xiaofang Wang, Hiroyuki Kawai, Craig Lee, David Lloyd, Stig Hansen
  • Patent number: 11573398
    Abstract: The present disclosure discloses an optical imaging lens group including, sequentially from an object side to an image side along an optical axis, a first lens having positive refractive power with a convex object-side surface; a second lens having refractive power; a third lens having refractive power; a fourth lens having refractive power; a fifth lens having refractive power; and a sixth lens having negative refractive power with a concave object-side surface and a convex image-side surface. A total effective focal length f of the optical imaging lens group, an entrance pupil diameter EPD of the optical imaging lens group and half of a maximal field-of-view Semi-FOV of the optical imaging lens group satisfy: f/EPD<2, and f*tan(Semi-FOV)>4.5 mm.
    Type: Grant
    Filed: August 18, 2020
    Date of Patent: February 7, 2023
    Assignee: Zhejiang Sunny Optical Co., Ltd.
    Inventors: Biao Xu, Kaiyuan Zhang, Xiaofang Wang, Fujian Dai, Liefeng Zhao
  • Patent number: 11548849
    Abstract: The present invention provides novel compounds (e.g., compounds of Formula I) which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: January 10, 2023
    Assignee: H. Lundbeck A/S
    Inventors: Mario Rottlander, Xiaofang Wang, Debasis Das, Jian Hong, Shu Hui Chen, Anette Graven Sams, Krestian Larsen
  • Patent number: 11547685
    Abstract: This document provides methods and materials for treating polycystic diseases such as polycystic kidney disease. For example, methods for using a TRPV2 agonist (e.g., probenecid) and optionally a vasopressin receptor antagonist (e.g., tolvaptan) to treat a mammal having polycystic kidney disease (e.g., autosomal dominant polycystic kidney disease) are provided.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: January 10, 2023
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Vicente E. Torres, Fouad T. Chebib, Peter C. Harris, Xiaofang Wang
  • Publication number: 20220396569
    Abstract: Provided herein are GLP-1 receptor modulator compounds, pharmaceutical compositions, methods of their preparation, and methods of their use in treatment, and/or diagnosis.
    Type: Application
    Filed: May 3, 2022
    Publication date: December 15, 2022
    Inventors: Xiaohui DU, Ray FUCINI, Xu RAN, Chien-Hung YEH, Xiang ZHOU, Subas Man SAKYA, Xiaofang WANG, Hiroyuki KAWAI, Craig LEE, Sumanta GARAI
  • Publication number: 20220380300
    Abstract: The present invention provides novel compounds which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.
    Type: Application
    Filed: July 20, 2022
    Publication date: December 1, 2022
    Applicant: H. Lundbeck A/S
    Inventors: Mario Rottlander, Anette Graven Sams, Xiaofang Wang, Debasis Das, Jian Hong, Shu Hui Chen
  • Publication number: 20220323470
    Abstract: The present disclosure relates to the field of medical technology, and in particular to a composition and the use thereof in the manufacture of a medicament for treating cancer. The present disclosure provides a composition containing a compound of formula I or a pharmaceutically acceptable salt, dimer or trimer thereof, and a tyrosine kinase activity inhibitor. The present disclosure shows through in vivo and in vitro anti-tumor tests that, based on the inhibitory effect of the tyrosine kinase activity inhibitor targeting VEGFR, EGFR and other receptor tyrosine kinases, the combination of Sotagliflozin and a tyrosine kinase activity inhibitor may exhibit a synergistic inhibitory effect on tumors, and the efficacy of the combination is significantly better than that of a single drug.
    Type: Application
    Filed: August 19, 2020
    Publication date: October 13, 2022
    Applicant: NEWISH TECHNOLOGY (BEIJING) CO., LTD.
    Inventors: Hailong QI, Xiaofang WANG, Zhongjie SUN
  • Publication number: 20220313652
    Abstract: The present disclosure relates to the field of medical technology, and in particular to use of a compound of formula I or a pharmaceutically acceptable salt, dimer or trimer thereof in the manufacture of a medicament for treating cancer. By testing the inhibitory effect on a variety of tumor cells, the results show that the compound of formula I has an inhibitory effect on tumor cells, with an IC50 of 40.77 ?M-182.5 ?M. In animal experiments, the compound of formula I shows a good inhibition effect on tumor volume, which is very significantly different from that of the solvent control group, p<0.05.
    Type: Application
    Filed: August 19, 2020
    Publication date: October 6, 2022
    Applicant: NEWISH TECHNOLOGY (BEIJING) CO., LTD.
    Inventors: Zhongjie SUN, Xiaofang WANG, Hailong QI
  • Publication number: 20220305072
    Abstract: The present invention relates to the field of medical technology, in particular to a composition for treating cancer and use and medicament thereof. The composition comprises an SGLT1 inhibitor and a VEGFR2 inhibitor. The present invention finds that SGLT1 interacts with VEGFR2 to promote the development and progression of tumors; the present invention also finds that a composition of a VEGFR2 targeting inhibitor and an SGLT1 inhibitor has a synergistic anti-tumor effect, and the composition of the VEGFR2 targeting inhibitor and the SGLT1 targeting inhibitor can be used in cancer treatment.
    Type: Application
    Filed: August 19, 2020
    Publication date: September 29, 2022
    Applicant: NEWISH TECHNOLOGY (BEIJING) CO., LTD.
    Inventors: Zhongjie SUN, Hailong QI, Ligong CHEN, Huangfan XIE, Defang LIU, Xiaoe E. YAN, Weiwei LI, Xiaofang WANG
  • Publication number: 20220280455
    Abstract: The present invention provides novel compounds which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.
    Type: Application
    Filed: July 30, 2020
    Publication date: September 8, 2022
    Applicant: H. Lundbeck A/S
    Inventors: Anette Graven Sams, Mario Rottlãnder, Xiaofang Wang, Debasis Das, Jian Hong, Shu Hui Chen, Jesper Frank Bastlund, Jelena Ivkovic, Karina Krøjer Søby, Morten Grupe Larsen
  • Patent number: 11434199
    Abstract: The present invention provides novel compounds which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.
    Type: Grant
    Filed: February 4, 2020
    Date of Patent: September 6, 2022
    Assignee: H. Lundbeck A/S
    Inventors: Mario Rottlander, Anette Graven Sams, Xiaofang Wang, Debasis Das, Jian Hong, Shu Hui Chen
  • Publication number: 20220244503
    Abstract: The present disclosure discloses an optical imaging lens group. The optical imaging lens group comprises, sequentially along an optical axis from an object side to an image side, a first lens, a second lens, a third lens, a fourth lens, a fifth lens, a sixth lens, a seventh lens and an eighth lens, wherein the first lens, the second lens, the third lens, the fourth lens, the fifth lens, the sixth lens, the seventh lens and the eighth lens have refractive powers. At least one lens in the first lens to the eighth lens has a non-rotationally symmetric aspheric surface; a total effective focal length fy of the optical imaging lens group in a Y-axis direction and a total effective focal length fx of the optical imaging lens group in an X-axis direction satisfy: fy/fx<0.8; and an f-number Fnoy of the optical imaging lens group in the Y-axis direction satisfies: Fnoy<2.9.
    Type: Application
    Filed: December 29, 2021
    Publication date: August 4, 2022
    Applicant: ZHEJIANG SUNNY OPTICS CO., LTD.
    Inventors: Xiaofang WANG, Xiaobin ZHANG, Jianke WENREN, Fujian DAI, Liefeng ZHAO
  • Publication number: 20220170375
    Abstract: The present invention belongs to the technical field of turbine cooling of aero-engine and gas turbine, and relates to the honeycomb-like helically cavity cooling structure of turbine blade. The honeycomb-like helically cavity cooling structure of turbine blade includes hollow turbine blade, honeycomb-like helically cavity and pin fins. Some cooling channels are arranged inside the hollow the hollow turbine blade, the cooling gas flows through the tunnels and cools the blade. Multi-arrays of honeycomb-like helically cavity are arranged in the blade wall, for cooling gas to enter and convective cooling. A cylindrical pin fin is arranged in the center of the honeycomb-like helically cavity. In each unit, the inlet hole and film hole are located on both sides of the blade wall, and the center lines of them are parallel in the same vertical plane.
    Type: Application
    Filed: December 15, 2020
    Publication date: June 2, 2022
    Inventors: Dong LV, Nan WANG, Xiaofang WANG, Xingao KONG, Yinan SUN
  • Publication number: 20220155560
    Abstract: The disclosure provides an optical imaging lens group, which sequentially includes from an object side to an image side along an optical axis: a first lens with a negative refractive power; a second lens with a refractive power; a third lens with a refractive power, an image-side surface thereof is a concave surface; a fourth lens with a negative refractive power; a fifth lens with a refractive power; and a sixth lens with a refractive power. Semi-FOV is a half of a maximum field of view of the optical imaging lens group, and Semi-FOV satisfies 45°<Semi-FOV<55°. A curvature radius R1 of an object-side surface of the first lens, a curvature radius R2 of an image-side surface of the first lens, a curvature radius R3 of an object-side surface of the second lens and a curvature radius R4 of an image-side surface of the second lens satisfy 0.5<(R1+R2)/(R3?R4)<1.5.
    Type: Application
    Filed: November 16, 2021
    Publication date: May 19, 2022
    Inventors: Xiaofang WANG, Fujian DAI, Liefeng ZHAO
  • Publication number: 20210318521
    Abstract: The present disclosure discloses an optical imaging lens assembly including, sequentially from an object side to an image side along an optical axis, a first lens having negative refractive power; a second lens having refractive power; a third lens; a fourth lens having refractive power, a convex image-side surface and a concave image-side surface; a fifth lens having refractive power and a concave object-side surface; a sixth lens; and a seventh lens. Half of a diagonal length ImgH of an effective pixel area on an imaging plane of the optical imaging lens assembly satisfies: ImgH?5.20 mm.
    Type: Application
    Filed: March 11, 2021
    Publication date: October 14, 2021
    Inventors: Xiaofang Wang, Kaiyuan Zhang, Fujian Dai, Liefeng Zhao